Why the study?
Numerous randomized trials comparing PCI with OMT alone in chronic coronary artery disease have yielded inconclusive prognostic results, leaving OMT as the first-line standard of care.
Does percutaneous coronary intervention (PCI) reduce myocardial infarction and mortality in patients with stable coronary syndromes?
Does percutaneous coronary intervention (PCI) reduce myocardial infarction and mortality in patients with stable coronary syndromes?
This review critically appraises the evidence and methodological pitfalls explaining why PCI has not demonstrated a prognostic advantage over optimal medical therapy in stable coronary artery disease.
Answers are grounded in this paper and cite their sources.
Consistent with optimal medical therapy in stable coronary syndromes; highlights methodological pitfalls requiring resolution in future trials.
Percutaneous coronary intervention (PCI) is widely adopted to treat chronic coronary artery disease. Numerous randomised trials have been conducted to test whether PCI may provide any prognostic advantage over oral medical therapy (OMT) alone, without definitive results. This has maintained the paradigm of OMT as the first-line standard of care for patients, reserving PCI for symptom control. In this review, we discuss the current evidence in favour and against PCI in stable coronary syndromes and highlight the pitfalls of the available studies. We offer a critical appraisal of the possible reasons why the existing data does not provide evidence supporting the role of PCI in improving clinical outcomes in patients with stable coronary syndromes.
No takes yet. Share an insight, caveat, or question.
Benenati et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: